Teprotumumab UpdateDec. 5, 2019
On Friday, Dec. 13th, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet in Silver Spring, MD to discuss teprotumumab, a potential treatment for active thyroid eye disease.
If you are interested in attending in person or submitting a comment to the FDA, please see this link for details.
The FDA's Advisory Committees provide independent advice from outside experts on issues related to human and veterinary drugs, biological products, medical devices, and ...